Page last updated: 2024-09-03

cyclo(prolylglycyl) and oxidopamine

cyclo(prolylglycyl) has been researched along with oxidopamine in 2 studies

Compound Research Comparison

Studies
(cyclo(prolylglycyl))
Trials
(cyclo(prolylglycyl))
Recent Studies (post-2010)
(cyclo(prolylglycyl))
Studies
(oxidopamine)
Trials
(oxidopamine)
Recent Studies (post-2010) (oxidopamine)
480288,63062,407

Protein Interaction Comparison

ProteinTaxonomycyclo(prolylglycyl) (IC50)oxidopamine (IC50)
Glyceraldehyde-3-phosphate dehydrogenaseHomo sapiens (human)8
DNA repair protein RAD52 homologHomo sapiens (human)0.779

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Antipov, TA; Gudasheva, TA; Kolisnikova, KN; Nazarova, GA; Seredenin, SB; Voronina, TA1
Antipova, TA; Gudasheva, TA; Koliasnikova, KN; Seredenin, SB1

Other Studies

2 other study(ies) available for cyclo(prolylglycyl) and oxidopamine

ArticleYear
[Similarity of cycloprolylglycine to piracetam in antihypoxic and neuroprotective effects].
    Eksperimental'naia i klinicheskaia farmakologiia, 2012, Volume: 75, Issue:9

    Topics: Animals; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Hypercapnia; Hypoxia; Mice; Mice, Inbred BALB C; Neuroprotective Agents; Oxidopamine; Peptides, Cyclic; Piracetam; Sympatholytics

2012
Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells.
    Doklady. Biochemistry and biophysics, 2016, Volume: 469, Issue:1

    Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Line; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glutamic Acid; Hippocampus; Humans; Mice; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Peptides, Cyclic; Piracetam

2016